Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23
Buy Rating on Neumora Therapeutics: Navigating Navacaprant's Potential in Neuropsychiatric Care
Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
5Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Neumora Therapeutics' Advancing Drug Pipeline Supports Buy Rating
Needham Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $23
Neumora Therapeutics Analyst Ratings
Neumora Therapeutics Analyst Ratings
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings
RBC Capital Reiterates Outperform on Neumora Therapeutics, Maintains $31 Price Target
RBC Capital Remains a Buy on Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Analyst Ratings